Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

ward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... 2011 Science, public health, and regulatory ... this document is designed for credentialed journalists. Release dates and ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
... 26, 2011 Kensey Nash Corporation (Nasdaq: ... Global Healthcare Conference in London on Tuesday, September 27th, ... the Company,s presentation at the Jefferies 2011 Global Healthcare ... approximately at 12:00 p.m. (ET).  To hear the live ...
Cached Medicine Technology:FDA News & Notes - Week of September 26, 2011 2
(Date:5/30/2015)... May 30, 2015 You've probably heard that ... and hearing loss. However, have you found a better way ... Olathe, Kan., have exactly what you need. , They developed ... build-up; dirt and dead, dry skin from the ears. What's ... swabs or anything on the market today for children and ...
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... 30, 2015 ProIntro Magnify contains 30 self-animating ... animations. Instantly add an elegant opening title to any ... range of clean design layouts. ProIntro Magnify is created exclusively ... extremely easy to use. Simply drag a preset into the ... and parameters in the Inspector window then watch as ProIntro ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall ... which she attributes to a lifetime of being health-conscious. She ... the release of her new book titled “ Cook for ... for Health and Longevity” features a collection of recipes and ... food . It is designed to encourage a lifestyle of ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 ... today that she is offering a free analysis and ... The offer coincides with Disability Awareness Month, which was ... Industry members across the United States such as Polk ... to raise awareness about the possibility of disability, as ...
Breaking Medicine News(10 mins):Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... MAKO Surgical Corp., a,developer of minimally invasive, ... that Frederic H. Moll, M.D.,has been named to ... Dr. Moll has over 20 years experience ... Hansen Medical Inc. in September 2002 and,currently serves ...
... Sept. 14 NNN Healthcare/Office REIT,Inc. has acquired ... closed on September 10, 2007. 2750 Monroe ... 106,000 square feet, as well as an accessory ... square feet, on a 10.5-acre parcel,in the Valley ...
... is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen some press reports about candidates for ... funds received from me, please return them in the form of a,donation to the DeBakey Medical ... ... ...
... AMERIGROUP,Corporation (NYSE: AGP ) will host an Investor ... held at the Grand Hyatt Hotel in New York ... management team,beginning at 8:30 a.m. Eastern Time. The ... of,AMERIGROUP,s National Advisory Board on Improving Healthcare Services for,Seniors ...
... following is a,statement by Mike Leavitt, Secretary of Health ... Rich McKeown, returns to Beijing as the,head of a ... my,Department, to begin formal negotiations on two binding Agreements ... of food and feed, and one on,the safety of ...
... PRGO ; TASE) today announced that President and CEO, ... a review of the Company,business for the financial community ... in New York. The meeting will be made ... or by phone at 866-383-5538, participant,code 10972. Presentations ...
Cached Medicine News:Health News:MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 3Health News:AMERIGROUP Corporation to Host Investor Day 2Health News:Perrigo Company to Host Analyst Meeting on September 18, 2007 2
... of America is the largest, ... lab network in the United ... Crizal coating centers, Essilor offers ... premium quality on the best-selling ...
Bambi database allows images, analytical results, and eyebank or clinical information to be stored in an easy-to-access database. In most cases, the analytical results from any of our analysis progra...
This computerized retail software is aimed for opticians/optometrists, optical chains/1 hr superstores, optical HMOs, and ophthalmology groups....
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
Medicine Products: